ÎÄÏ××ÊÁÏ
ÁªÏµ918²«ÌìÌÃ
918²«ÌìÌÃ
µç»°£º0570£8788056
´«Õ棺0570£8788381
ÓÊÏ䣺zjgykp@163.com
µØµã£ºÕã½Ê¡áéÖÝÊж«¸Û¾¼Ã¿ª·¢Çø
¶«¸Û4·2ºÅ
- ¸ÄÁ¼¸ÌéÙ¹û½º£¨MCP£©Ôö¼ÓÄÐÐÔÇ°ÁÐÏÙ°©»¼ÕßÇ°ÁÐÏÙÌØÒìÐÔ¿¹Ô±¶Ôöʱ¼ä£ºµÚ¶þ½×¶ÎÊÔÑéÑо¿
- Ðû²¼Ê±¼ä£º 2018/12/26¡¡µã»÷´ÎÊý£º2793¡¡
-
¸ÄÁ¼¸ÌéÙ¹û½º£¨MCP£©Ôö¼ÓÄÐÐÔÇ°ÁÐÏÙ°©»¼ÕßÇ°ÁÐÏÙÌØÒìÐÔ¿¹Ô±¶Ôöʱ¼ä£ºµÚ¶þ½×¶ÎÊÔÑéÑо¿
Ç°ÁÐÏÙ°©ºÍÇ°ÁÐÏÙ¼²²¡£¨2003£©6£¬301-304
×÷ÕߣºBW Guess, MC Scholz, SB Strum, RY Lam, HJ Johnson & RI Jennrich ÒëÕߣºTiffany Yang
ÊÔÑéͨ¹ýÑо¿13Àý¾Ö²¿ÖÎÁƼ´Ç°ÁÐÏÙ°©¸ùÖÎÊõ£¬·øÉä»òÀ䶳ºóÉú»¯Ç°ÁÐÏÙÌØÒ쿹ԣ¨PSA£©Ê§Ð§µÄ13ÃûÄÐÐÔÇ°ÁÐÏÙ°©»¼ÕßÒÔÑо¿¸ÄÐÔ¸ÌéÙ¹û½º(¹û½ºÈÜÒº)µÄÄÍÊÜÐÔºÍ×÷Óá£13ÃûÄÐÐÔ½øÐÐÁËÆÀ¼ÛÄÍÊÜÐԲⶨ£¬10Ãû½øÐÐÁËÁÆЧÆÀ¶¨¡£10È˵ÄÇ°ÁÐÏÙÌØÒìÐÔ¿¹Ô±¶Ôöʱ¼ä£¨PSADT£©µÄ±ä¸ïÊÇÑо¿µÄÖ÷Òª½á¹û¡£ÎÒÃÇ·¢Ã÷£¬Óë·þÓÃMCPÇ°Ïà±È£¬·þÓÃMCP12¸öÔºó10ÈËÖеÄ7ÈË£¨70£¥£©PSADTÔö¼Ó£¨PֵСÓÚ0.05£©¡£ÕâÏîÑо¿±êÃ÷£¬MCP¿ÉÄÜ»áÑÓ³¤ÄÐÐÔ¸´·¢Ç°ÁÐÏÙ°©»¼ÕßµÄPSADT¡£
Òªº¦´Ê£ºÇ°ÁÐÏÙÌØÒìÐÔ¿¹Ô±¶Ôöʱ¼ä;¸ÄÐÔ¸ÌéÙ¹û½º;»Ø¹éÆÊÎö
½éÉÜ
×î½ü¹ØÓÚ¸ÌéÙ¹û½ºÖÎÁÆ°©Ö¢µÄÑо¿Êܵ½¹Ø×¢£¬¸ÌéÙ¹û½ºÊÇÒ»ÖÖ´Ó¸ÌéÙÀàË®¹ûÈçÄûÃÊ£¬ÆÏÌÑèÖ£¬éÙ×Ӻ͸̵ĹûƤºÍ¹ûÈâÖз¢Ã÷µÄÌìÈ»ÎïÖÊ¡£¸ÌéÙ¹û½ºÊÇÒ»¸öÅÓ´óµÄ¶àÌÇ£¬¾ßÓи»ºñµÄ°ëÈéÌÇ£¨ÌÇ̼ˮ»¯ºÏÎ²Ð»ù¡£ÔÚʵÑéÊÒÖУ¬¸ÌéÙ¹û½ºÍ¨¹ýµ÷½âpHÖµÀ´±¬·¢½ÏСµÄ¶ÌÁ´´Ó¶ø¸ÄÐÔ£¨MCP£©£¬Ê¹µÃ¸üÈÝÒ×±»ÈËÀ೦µÀÎüÊÕ¡£
Ñо¿±êÃ÷£¬Ï¸°ûÓëϸ°ûµÄÏ໥×÷ÓÃÓɳÆΪ̼ˮ»¯ºÏÎï½áºÏÂÑ°×£¨CBP£©»òÄý¼¯ËØϸ°ûµÄÍâò·Ö×ӽ鵼¡£ÕâÑùµÄÒ»¸öÍâÔ´Äý¼¯ËØ£¬°ëÈéÌÇÄý¼¯ËØ-3£¬ÓëתÒÆÀú³ÌÏà¹Ø£¬²¢ÇÒÔÚתÒÆÀú³ÌÖбÈÔ·¢Ö×Áöϸ°û¸ü¶àµÄÌåÏÖ¡£°ëÈéÌÇÄý¼¯ËØÌåÏÖˮƽÓë´ó³¦°©£¬Î¸°©£¬¼××´ÏÙ°©Ö×ÁöµÄ²î±ð½×¶Î±£´æ¹ØÁªÐÔ¡£ ¿¹°ëÈéÌÇÄý¼¯Ëص¥¿Ë¡¿¹ÌåÒ²±»Ö¤Ã÷Äܹ»ÒÖÖÆÖ×Áöϸ°ûµÄÉú³¤¡£¾ÝÍƲ⣬ÕâЩ¸ß°ëÈéÌÇÄý¼¯ËØˮƽ»áÔì³ÉÖ×Áöϸ°ûÔÚ¡°Ä¿±êλÖᱸü¶àµÄÕ³ÔÞͬ¾Û¼¯£¬¼´×ªÒƲ¿Î»¡£
MCP×÷Ϊ°ëÈéÌÇÄý¼¯ËØ-3ÊÜÌå´¦µÄÅäÌ壬½áºÏ°ëÈéÌÇÄý¼¯ËØ-3£¬´Ó¶ø×è¶ÏÖ×Áöϸ°ûÏ໥¾Û¼¯µÄÄÜÁ¦¡£Õâ×èÖ¹ÁËÖ×Áöϸ°ûµÄ¾Û¼¯ÒÔ¼°Ö®ºó¶ÔÄ¿±êλÖÃÈçѪ¹ÜÄÚƤϸ°ûµÄ¸½×ÅÁ¦¡£
1995Ä꣬Ƥ¶÷ËþµÈÈËͨ¹ýMAT-LyLuµËÄþR3327´óÊóµÄ±ÈÕÕÊÔÑéÑо¿MCP¶Ô·ÎתÒÆÉú³¤½ø¶ÈµÄÓ°Ïì¡£MATLyLuÖ×ÁöÊÇÒ»ÖÖµÍÆÊÎöµÄѸËÙÉú³¤µÄµËÄþR3327´óÊóÇ°ÁÐÏÙ°©ÏÙ°©Ä£ÐÍÑÇϵ¡£´óÊóͨ¹ýÒûÓÃË®»ñµÃ0.1»ò1£¥µÄMCP»òÕß²»±»ÖÎÁÆÒÔ±ÈÕÕ¡£ÕâÏîÑо¿µÄ½á¹û
±êÃ÷£¬ 15/16£¨93.75£¥£©µÄ±ÈÕÕ¶¯Îﱬ·¢ÁË·ÎתÒÆ£¬ÓëÖ®±È½Ï0.1£¥MCPÖÎÁÆ×éΪ7/14£¨50£¥£©£¬1£¥MCP×éΪ9/16£¨56.3£¥£©¡£±ðµÄ£¬1£¥MCP ×éÓÐ13£¥µÄÀÏÊó±»·¢Ã÷ÓÐÁÜͶºÏתÒÆ£¬Ïà±È±ÈÕÕ×éµÄ±ÈÂÊΪ55£¥¡£
ÔÚÁíÒ»ÏîÌåÄÚÑо¿ÖУ¬MCP±»Ö¤Ã÷ÄÜͨ¹ý×è¶Ï°ëÈéÌÇÄý¼¯ËØ-3ÓëÆäÊÜÌåµÄ¹ØÁªÒÖÖÆÌÇÀà½éµ¼µÄѪ¹ÜÉú³É£¬´Ó¶øÒÖÖÆÈéÏٺͽ᳦Ö×ÁöµÄÉú³¤ºÍתÒÆ¡£
ÓÉÓÚ°ëÈéÌÇÄý¼¯ËØ-3Òѱ»Ö¤Ã÷ÊÇ·ºÆðÓÚÈËÀàÇ°ÁÐÏÙ°©Ï¸°ûÖêPC-3£¬Ò²±»·¢Ã÷·ºÆðÓÚÈËÀàÇ°ÁÐÏÙ°©×éÖ¯ÖУ¬ÎÒÃǽøÐÐÁËÒ»¸ö½×¶Î¶þÊÔÑéÑо¿£¬¶Ô13ÀýÇ°ÁÐÏÙ°©µÄÄÐÐÔʹÓÃMCP¡£¾Ö²¿ÖÎÁƺ󣨼´Ç°ÁÐÏÙ°©¸ùÖÎÊõ£¬·øÉä»òÀ䶳£©Ñо¿ÖÐËùÓÐÈ˵ÄPSA¶¼´®ÐÐÔö¼Ó¡£Ñо¿µÄÄ¿µÄÊÇÈ·¶¨MCP¹ØÓÚÔö¼ÓÇ°ÁÐÏÙÌØÒìÐÔ¿¹Ô±¶Ôöʱ¼ä£¨PSADT£©µÄЧ¹û¡£
²¡È˺ÍÒªÁì
Ñо¿ÐÒé±»µ¤Äá¶û¡¤¸¥ÀïÂü¼ÍÄîҽԺʹÓÃÖƶȼìÌÖίԱ»áÅú×¼ÓÃÓÚÉæ¼°ÈËÀàÊÜÊÔÕßµÄҽѧÑо¿¡£ËùÓÐÑо¿µÄ¼ÓÈëÕßÔÚ¼ÓÈëʵÑéÇ°ÖªÇéͬÒâ¡£
ÕâÊÇÒ»Ïî·ÇËæ»úMCPI¶þÆÚÊÔÑéÑо¿¡£ÊµÑéÖÐÿ¸ö²¡È˶¼µ£µ±×Ô¼ºµÄ±ÈÕÕ¹¤¾ß£¬ÒòΪÊDZȽϸÉԤ֮ǰºÍÖ®ºóµÄÇ°ÁÐÏÙÌØÒ쿹ԣ¨PSA£©µÄ±ä¸ï»òPSADT¡£ÊµÑé֮ǰ¼°ÊµÑéÆڼ仼Õß±»½¨Òé²»ÏÔ×űä¸ïËûÃǵÄÒûʳ£¬»òʹÓÃÆäËûÓªÑøºÍÄ¿½ñµÄ´¦·½Ò©¡£
±¾Ñо¿Ñ¡ÔñµÄ»¼Õß¾»î¼ì֤ʵÓÐÇ°ÁÐÏÙ°©£¬ÔÚ¼ÓÈëʵÑé֮ǰδ¾ÖÎÁÆ£¬ÓеͿÉÊÇÖð²½ÉÏÉýµÄPSAˮƽ£¨Ð¡ÓÚ10ºÁ΢¿Ë/ºÁÉý£©¡£ËùÓÐÄÉÈëÑо¿µÄ»¼ÕßÔÚ¾Ö²¿¸ùÖÎÐÔÖÎÁƺóÉú»¯PSAʧЧ£¨ÈçÇ°ÁÐÏÙ°©¸ùÖÎÊõ£¬ÍâÕÕÉ䣬»òÀ䶳ÁÆ·¨£©£¬8Ãû»¼Õß֮ǰʹÓùýÐÛ¼¤ËØ°þ¶áÁÆ·¨£¨ADT£©¡£ÔÚ²»Áè¼Ý6¸öÔµÄʱ¼ä¼ä¸ôÖл¼ÕßÖÁÉÙÓÐÈý¸öÉÏÉýµÄPSAˮƽ¼Í¼¡£ÔÚ¼ÓÈë´ËÏîʵÑéÖÁÉÙ6¸öÔÂÇ°£¬Ö®Ç°½ÓÊܹýADTµÄ»¼Õß±ØÐëÓÐÒ»¸öÎȶ¨»òÎÈ̬´óÓÚ¼´ÊÇ150ºÁ΢¿Ë/ºÁÉýµÄѪÇåغͪˮƽ¡£
¼ÓÈëÕßµÄÆÀ¶¨ÓÉÒ½Éú¶ÔÆä»ùÏßÌå¼ì¿ªÊ¼£¬ÏµÍ³Éó²é£¬²¢Ê¹ÓÃECOG±ê×¼½øÐÐÐÔÄÜ×´¿öµÄÆÀ¹À¡£ÊÔÓÃÆÚ¼äԼĪÿ4ÖÜÖظ´Ò»´ÎϵͳÉó²é£¬ECOGÆÀ¹À£¬PSA£¬»¯Ñ§ºÍ¸Î°å¡£
Ñо¿ÖеÄÿ¸ö¼ÓÈëÕ߶¼ÒÔ·ÛÄ©Ìî³ä½ºÄÒµÄÐÎʽ·þÓÃ800ºÁ¿ËPectaÈܽº£¨EconugenicsÊ¥ÂÞɯ£¬¼ÓÀû¸£ÄáÑÇ£©¡£Ã¿ÈÕPectaÈܽº×ÜÓÃÁ¿Îª18Á££¨14.4¿Ë£©£¬Óë8°»Ë¾Ë®»ò¹ûÖÒ»Æð·Ö3´Î·þÓᣠ²¡È˶ÔPectaÈܽºµÄÄÍÊÜÐÔ½øÐÐÁËÆÀ¹À£¬²¢ÓëÿÖÜ×ÔÎÒ»ùÏßÆÀ¹ÀÈռǵĽá¹û±È½Ï¡£Ã»ÓÐÕýʽҪÁì¿ÉÒÔÈ·¶¨»¼ÕßÇкϻ®¶¨ÓÃÁ¿Ê¹ÓÃPectaÈܽº¡£È»¶ø£¬Ñо¿ÕßÿÔ¶¼»áѯÎʼÓÈëÕß¹ØÓÚʵÑéµÄºÏ¹æÐÔ£¬ËùÒÔÕâ±»ÈÏΪÊÇÍêÈ«Çкϻ®¶¨µÄ¡£
ÕâÏîÑо¿µÄÖ÷Òª½á¹ûÊÇʹÓÃMCP֮ǰºÍÖ®ºóPSA»òPSADTµÄ±ä¸ïÂÊ¡£Ê¹ÓÃMCP ֮ǰºÍÖ®ºóPSAÔÚÏàͬµÄ»¯ÑéÊÒÓÉͬһ¼¼ÊõԱƵ·±ÕÉÁ¿£¨´ó´ó¶¼Çé¿öÏÂÿÔ£©¡£PSAÓÃImmulite IµÚÈý´ú£¨Õï¶Ï²úÆ·¹«Ë¾£¬ÂåÉ¼í¶£¬¼ÓÀû¸£ÄáÑÇ£¬ÃÀ¹ú£©Õï¶Ï£¬ÊÇÒ»¸öÍêÈ«×Ô¶¯»¯£¬³¬ÁéÃôµÄ»¯Ñ§·¢¹â¼ì²â·¨£¬ÁéÃô¶È¼«ÏÞΪ0.003ºÁ΢¿Ë/ºÁÉý¡£
ÄÐÐÔÇ°ÁÐÏÙ°©ÓйصÄÑо¿±êÃ÷Èô²»½øÐиÉÔ¤PSAˮƽ»áÁ¬ÐøÔö¸ß¡£µ±ÌåÏÖΪ log PSAʱ£¬Ëæ×Åʱ¼äµÄÍÆÒÆPSA°´ºã¶¨ÏßËÙ¶ÈÔö¼Ó¡£ÑªÇåPSAˮƽÒѱ»Ö¤Ã÷ÊÇÇ°ÁÐÏÙ°©Ôö³¤µÄÒ»¸ö¿É¿¿µÄÌæ´ú±ê¼Ç£¬Òò´ËPSADTÔö¼ÓÒâζ×ÅÖ×Áö¼õÉÙÔö³¤¡£
ͳ¼ÆÆÊÎö
ÓÐÁ½ÖÖ³£ÓõÄÒªÁìÅÌËãPSADT¡£¶¼»áʹÓù«Ê½£¨X£¬Y£©=£¨Ê±¼ä£¬log PSA£©¡£µÚÒ»ÖÖÒªÁìֻʹÓõÚÒ»¸öºÍ×îºóÒ»¸öµã£¬ÒÔ¼°Á¬½ÓËûÃǵÄÏßµÄбÂÊ¡£µÚ¶þ¸öʹÓÃÁ¬½ÓËùÓпÉÓõãµÄÖ±ÏßµÄбÂÊ¡£ÎÞÂÛÊÇÄÄÖÖÇé¿ö£¬PSADTÊÇ2µÄ¶ÔÊý³ýÒÔбÂÊ¡£
ËäȻʹÓÃÕâÁ½ÖÖÒªÁìÏ»ñµÃµÄÖµÍùÍùÊÇÏàËƵģ¬Ê¹ÓÃËùÓÐÊý¾Ý¸üºÃ£¬ÒòΪÓëµ¥µ¥Ê¹ÓÃÁ½¸öÊý¾Ýµã±È¿ÉÒÔ±¬·¢¸üСµÄ¹ÀËãÖµ·½²î¡£ÓÉÓÚÏßÐԻعéʹÓÃËùÓпÉÓõÄÊý¾Ý´Ó¶ø¸ü׼ȷ£¬ËùÒÔËüÊÇÅÌËãPSADT****µÄÒªÁ졣Ȼ¶ø£¬ÅüÃæ¶ÔÅÌË㣬Ȼºó±È½Ï¿ªÊ¼ÖÎÁÆÇ°ºóµÄPSADTʱ£¬Ò»Ð©ÎÊÌⱬ·¢ÁË¡£µÚÒ»¸ö¿ÉÄÜÊʺÏÁ½¸ö¶ÀÁ¢µÄ»Ø¹éÏßÀ´ÅÌËãÖÎÁÆÇ°ºóµÄPSADTs£¬µ«Ö®ºóÕâÒ»ºÏÊÊ»áÔÚ¿ªÊ¼ÖÎÁÆʱ¼ä¶Ï¡£±ðµÄ£¬ËüÃæÁÙ×ÅÌØÁíÍâÈÎÎñÀ´ÆÀ¼ÛÔÚÁ½¸ö±¶Ôöʱ¼äÖÐÈÎÒ»ÊÓ²ì²î±ðµÄÒâÒå¡£
ÕâЩÎÊÌâÊÇ¿ÉÒÔÓÃÎÒÃÇÍŶÓÏÈÇ°ËùÃèÊöµÄʹÓÃ×îºÃÄâºÏÑùÌõÏßµÄÐÂÒªÁì¿Ë·þ¡£×îºÃÄâºÏÑùÌõÏßµÄÒªÁìÀ´ÕÉÁ¿ºÍ±È½ÏÖÎÁÆÇ°ºóµÄPSADT±È½Ï¼òµ¥µÄ£¬µ«×¼È·¡£¸ÃÒªÁìÉ漰ʹÓõ¥»Ø¹éÆÊÎöÀ´´¦ÀíËùÓеÄÇ°ºóÊý¾Ý£¬À´ÄâºÏÖÎÁÆ¿ªÊ¼Ê±t0µÄÕÛÏß¡£ÕâÊÇ9ºÅ»¼ÕßʹÓÃMCPÖÎÁÆÇ°ºóPSAÕÉÁ¿ÖµµÄÆÊÎö£¬¼û±í1£¨¼ûͼ1£©¡£»Ø¹éÄ£ÐÍÊÇ£º
y=¦Á+¦Ât+¦Ãs£¨t£© £¨1£©
ÆäÖÐy=log£¨PSA£©£¬tÊÇʱ¼ä£¬ºÍS£¨t£©=****Öµ£¨t£t0£¬0£©¡£ÔÚÕâÀS£¨t£©ÊÇÒ»¸ö»ù±¾µÄÏßÐÔÑùÌõ£¬ÔÚt0´¦ÓÐÒ»¸ö½á¡£
¸ÃÒªÁì¿Ë·þÁËÇ°ÃæÌáµ½µÄÎÊÌâ¡£ËüʹÓÃÁËËùÓÐÊý¾Ý£¬ÇкÏÔÚÖÎÁÆ¿ªÊ¼Ê±Ã»ÓÐÌøÔ¾£¬PSADTs²î±ðÏÔÖøÐÔ½ö½öÊǦùÀÖµµÄÏÔÖøÐÔ¡£Õâ¿ÉÒÔÖ±½Ó´Ó»Ø¹éÊä³ö¶ÁÈ¡¡£
½á¹û
¹²ÓÐ13Àý»¼Õß±»ÄÉÈëÑо¿£¬ÆäÖÐ10Àý¿ÉÆÀ¼ÛÁÆЧ¡£±í1ÁгöÁË10λÆÀ¹À»¼ÕߵIJ¡ÈËÌØÕ÷¡£±í2ÁгöÁËPSADT¶ÔMCPµÄ·´Ó¦¡£ÒÔÑо¿Ç°Ïà±È1 0Ãû»¼ÕßÖеÄ8Ãû£¨80£¥£©Ñо¿ºóPSADTÔö¼Ó¡£È»¶ø£¬10ÈËÖ»ÓÐ7ÈË£¨70£¥£©ÓÐͳ¼ÆѧÒâÒ壨PֵСÓÚ¼´ÊÇ0.05£©¡£Ã»Óв¡È˵ľø¶ÔPSAϽµ¡£
10Ãû±»ÆÀ¼ÛµÄ»¼ÕßMCPµÄÄÍÊÜÐÔÁ¼ºÃ¡£ 3Àý»¼Õߣ¨23£¥£©ÓÉÓÚ¸±×÷Óã¨Çá¶È¸¹²¿¾·ÂΣ¬Çá¶È¸¹Ðº£©Í˳öÑо¿£¬Í£Ö¹MCPºóÂíÉϾͻñµÃÁË»º½â¡£²¡ÈËÖÐûÓзºÆðÈκÎÑÏÖصĸ±×÷Óá£
ÌÖÂÛ
ÎÒÃÇÑо¿µÄÖ÷Òª½á¹ûÊÇÊÇÇ°ÁÐÏÙ°©ÄÐÐÔ»¼Õß·þÓÃMCPºóPSADTÓÐÎÞ±ä¸ï¡£10ÈËÖÐÓÐ7È˺Í֮ǰµÄ×Ô¼º±ÈÕÕPSADTÏÔ×ÅÔö¼Ó¡£Ö±¹ÛµØ˵£¬PSAˮƽ·±¶µÄËùÐèʱ¼äÈôÁ¬ÐøÔö³¤½«Òâζ×Å°©Ö¢½øÕ¹»áÂýһЩ£¬ÓÉ´Ë¿ÉÒÔµ¼ÖÂÊÙÃüµÄÑÓ³¤¡£
¶à¸öÑо¿±¨¸æÁËPSADT¹ØÓÚÔ¤²âÄÐÐÔÇ°ÁÐÏÙ°©½ø³ÌµÄÁÙ´²Ó¦ÓüÛÖµ¡£ÔÚÒ»¸ö³ö×ÔÅӵµı»¹ã·ºÒýÓõÄÎļþÖУ¬¸ùÖÎÊõºóÉú»¯PSA¸´·¢µÄÄÐÐÔÇ°ÁÐÏÙ°©»¼ÕßPSADTСÓÚ»ò¼´ÊÇ10¸öÔÂԤʾ×ÅתÒÆÐÔ°©Ö¢Éú³¤µÄ¼¸ÂʺÍʱ¼ä¡£ÂÞ²®´ÄµÈÈË·¢Ã÷Èô»¼ÕßPSADTÉÙÓÚ6¸öÔÂ
Ôò¹ØÓÚϵͳÐÔ½øÕ¹£¨SP£©µÄ5-Y×ÔÓɶÈÖ»ÓÐ64£¥¡£Ïà·´£¬ËûÃÇ·¢Ã÷ÈôPSADT³¤ÓÚ1ÄêÔò¹ØÓÚϵͳÐÔ½øÕ¹£¨SP£©µÄ5-Y×ÔÓɶÈΪ95£¥¡£Ã÷È··ÅÁƺóµÄ¶ÌPSADTҲԤʾןü¶àѸËÙ¶ñ»¯µÄÖ¢×´±¬·¢¡£½öͨ¹ýÊÓ²ìÒѱ»Ö¤Ã÷ÄÐÐÔPSADTÊÇ°©Ö¢Ô˶¯×îÃ÷ÏÔµÄÖ¸±ê¡£
ËäȻͨ¹ýPSADTÀ´×ÊÖúÔ¤²â½«»á±¬·¢ÁÙ´²½¥½øÐÔ°©Ö¢µÄ²¡È˵ÄÒªÁìÒѾ½¨Á¢£¬µ«ÉÐδÃ÷È·ÖÎÁÆÒªÁìÊÇ·ñ¸Ä±ä»ò±¶Ôöʱ¼äÊÇ·ñ»áÓ°ÏìÁÙ´²½á¹ûµÄȨºâ£¬ÈçתÒÆÐÔ¼²²¡µÄÉú³¤»òÉú´æÆÚµÄÑÓ³¤¡£
PSADTµÄÓÐÀû±ä¸ï¿ÉÄÜÓÐÓâÔ½¶Ô°©Ö¢¸öÌåÉú´æDZÔÚÓ°ÏìÖ®ÍâµÄÑо¿Ó¦Óá£ÆÀ¼ÛʹÓÃÒ©¼ÁºóPSADTµÄ±ä¸ï¿ÉÄÜ»á³ÉΪһÖÖÓÐЧµÄÌåÄÚÒªÁìÀ´É¸Ñ¡ÎÞ¶¾Ò©¼Á¡£¿ÉÒÔÏëÏóµÄÊÇ£¬Çá΢ÓÐЧµÄÒ©ÎÔö¼ÓPSADT£¬µ«²»»áµ¼ÔÚPSAϽµ£©£¬µ±ÓëÆäËû¿¹°©Ò©Îï×éºÏʹÓÃʱ¾ßÓкܸߵÄÁÙ´²¼ÛÖµ¡£
ÒÔÍù1,25-¶þôÇάÉúËØD3£¨¹Ç»¯Èý´¼£©µÄÑо¿Ö¤Ã÷ÁËÕâ¸öÏë·¨¡£µÚÒ»ÏîÑо¿¹Ø×¢ÁËÓëÖÎÁÆÇ°Ïà±È£¬Èý´¼Ã¿ÈÕ¼õ»º7ÃûÔçÆÚ¸´·¢ÐÔÇ°ÁÐÏÙ°©ÄÐÐÔ»¼ÕßPSAÉÏÉýËÙÂʵÄ×÷Óá£Ñо¿·¢Ã÷£¬ÓëÈý´¼ÖÎÁÆÇ°Ïà±È£¬ÆßÃûÖеÄÁùÃû»¼ÕßPSADTÏÔÖøÔö¼Ó¡£µÚ¶þÏîÑо¿ÆÀ¼ÛÁË22Ãû¸´·¢ÐÔÇ°ÁÐÏÙ°©Ö¢ÄÐÐÔ»¼ÕßµÄÿÖÜÂö³å£¨¸ß¼ÁÁ¿£©Èý´¼¡£ 3Àý»¼Õß±»È·ÈÏPSA¼õÉÙ£¬ÈýÀýÌØÁíÍ⻼ÕßPSADTÏÔÖøÔö¼Ó¡£
ÔÚÕâЩ½á¹ûµÄ»ù´¡ÉÏ£¬¿ªÕ¹Á˸߼ÁÁ¿Âö³åÈý´¼½áºÏ¶àÎ÷×Ïɼ´¼£¨Taxoteres£©µÄÑо¿£¬Óëµ¥¼Á¶àÎ÷×Ïɼ´¼Ïà±È£¬ÒÑÓëÍíÆÚÇ°ÁÐÏÙ°©ÄÐÐÔ»¼Õ߸üƵ·±£¬¸üÉîÈëµÄPSAϽµÏÔʾ³öÏÔ×ŵÄÐͬ×÷Óá£
ÏÔÈ»£¬ÔÚÓÃÒ©¼ÁÈçMCP¸ÉÔ¤ºóPSADTµÄ±ä¸ïÐèÒª½÷É÷´¦Àí¡£ÓÉÓÚÎÒÃDz»¿ÉÖ±½ÓÕÉÁ¿Ö×ÁöÌå»ý£¬ÎÒÃDz»ÖªµÀÕâЩ±ä¸ïÊÇÓÉÓÚ°©Ï¸°ûµÄËÀÍö»òÆäËûһЩ¸Ä±äPSAµÄ»úÖÆ¡£ÎÒÃÇ12¸öÔµÄÑо¿ÆÚ¼ä¹ØÓÚÆÀ¹ÀMCP¶ÔPSADTÓ°ÏìÊdzä·ÖµÄ£¬µ«ÏÔÈ»Õâô¶ÌµÄʱ¼äÄÚÊDz»·óÆÀ¹À¶ÔÇ°ÁÐÏÙ°©PSADT±ä¸ïµÄºã¾ÃÓ°ÏìµÄ¡£
½áÂÛ
ÔÚÕâÏîÑо¿ÖУ¬ÎÒÃÇÊÔͼȷ¶¨Ò»ÖÖÓªÑøÔö²¹¼ÁMCP£¨¹û½ºÈÜÒº£©¹ØÓÚ10Ãû¾Ö²¿¸ùÖÎÐÔÖÎÁƺóÉú»¯PSAʧЧµÄÄÐÐÔÇ°ÁÐÏÙ°©»¼ÕßPSA»òPSADTÔö³¤ÂÊ¡£
·þÓÃMCP12¸öÔºó£¬ÎÒÃÇÊӲ쵽Óë·þÓÃMCPÇ°Ïà±È£¬10Àý»¼ÕßÖÐÓÐÆßÀý£¨70£¥£©ÓÐͳ¼ÆÒâÒåϵģ¨PֵСÓÚ0.05£©PSADTÏÔÖøÔö³¤¡£
MCP¹ØÓÚ°©Ö¢½ø³ÌµÄºã¾ÃÓ°ÏìÈÔȻδ֪¡£ÈÔÐèÒª¸ü¶àµÄÑо¿À´È·¶¨MCPÔÚÖÎÁÆÇ°ÁÐÏÙ°©ÖеÄ×÷Óá£
Modified citrus pectin (MCP)increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II
pilot studyBW Guess *, MC Scholz , SB Strum , RY Lam , HJ Johnson & RI Jennrich
1Prostate Oncology Specialist, Marina del Rey, California, USA; Medical Oncologist,
Ashland, Oregon, USA; and Department of Statistics, University of California at Los Angeles, Los Angeles, California, USAThis trial investigated the tolerability and effect of modified citrus pectin(Pecta-Sols) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy,radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-valueo0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking MCP. This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer.
Prostate Cancer and Prostatic Diseases (2003) 6, 301¨C304. doi:10.1038/sj.pcan.4500679Keywords: prostate-specific antigen doubling time; modified citrus pectin; spline regression
- ÉÏһƪ£º¿Ú·þ¸ÄÐÔ¸ÌéÙ¹û½ºÒÖÖÆ´óÊóÇ°ÁÐÏÙ°©Ä£ÐÍÖеÄ×Ô·¢×ªÒÆ
ÏÂһƪ£ºÐ¡Êó½á³¦Ö×ÁöÄ£ÐÍÖиÄÐÔ¸ÌéÙ¹û½º¶Ô¸ÎÔàתÒƵÄÒÖÖÆ×÷Óà - ·µ»ØÐÂÎÅÁбí